How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/percutaneous-coronary-intervention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Percutaneous coronary intervention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Percutaneous coronary intervention (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Percutaneous coronary intervention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Kengreal	CANGRELOR	Chiesi	P2Y12 Platelet Inhibitor [EPC]	P2Y purinoceptor 12	2015-01-01
Effient	PRASUGREL	Cosette	P2Y12 Platelet Inhibitor	P2Y purinoceptor 12	2009-01-01
Argatroban	ARGATROBAN	Hikma Pharm Co Ltd	Anti-coagulant [EPC]	Prothrombin	2000-01-01
Angiomax	BIVALIRUDIN	Novartis	Anti-coagulant [EPC]	thrombin	2000-01-01
Aggrastat	TIROFIBAN	Medicure	Platelet Aggregation Inhibitor	Integrin alpha-IIb/beta-3	1998-01-01
Integrilin	EPTIFIBATIDE	Merck & Co.	Platelet Aggregation Inhibitor [EPC]	Integrin alpha-IIb/beta-3	1998-01-01
Reopro	ABCIXIMAB	Johnson & Johnson		Integrin alpha-IIb/beta-3	1993-01-01
Iopidine	APRACLONIDINE	Harrow Health	alpha-Adrenergic Agonist	Alpha-2A adrenergic receptor	1987-01-01
Brilinta	Brilinta	AstraZeneca		Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta	ticagrelor	AstraZeneca	P2Y12 Platelet Inhibitor [EPC]	Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Percutaneous coronary intervention
Chiesi · 1 drug in Percutaneous coronary intervention
Cosette · 1 drug in Percutaneous coronary intervention
Harrow Health · 1 drug in Percutaneous coronary intervention
Hikma Pharm Co Ltd · 1 drug in Percutaneous coronary intervention
Johnson & Johnson · 1 drug in Percutaneous coronary intervention
Medicure · 1 drug in Percutaneous coronary intervention
Merck & Co. · 1 drug in Percutaneous coronary intervention
Novartis · 1 drug in Percutaneous coronary intervention
· 1 drug in Percutaneous coronary intervention
University of Cincinnati · 1 drug in Percutaneous coronary intervention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Percutaneous coronary intervention:

Cite this brief

Drug Landscape (2026). Percutaneous coronary intervention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/percutaneous-coronary-intervention. Accessed 2026-06-10.

Percutaneous coronary intervention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing